Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY
Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.
How this was made
The 30-second read
Why it matters
Collective catalyst‑driven moves suggest a sector‑wide bullish bias, but individual stock fundamentals will dictate durability.
Market read
Multiple biotech stocks achieving new highs on fresh regulatory and commercial news indicate a short‑term sector rally.
What to watch
Execution risk on new product rollouts and potential reimbursement delays could temper gains.
Background
The article aggregates recent 52‑week highs across five biotech firms, each driven by distinct regulatory or commercial catalysts.
Ticker impact
CareDx hit a 52‑week high of $63.09 after Medicare coverage was announced for its AlloSure, AlloMap and AlloSeq systems.
upward pressure over the next weeks
Medicare coverage expands payer base and validates the product suite.
Adaptive Biotechnologies rose over 6% to a 52‑week high after receiving NCCN guideline endorsement for its MRD test.
moderate upside in the near term
Clinical guideline inclusion is a strong commercial catalyst.
Revvity reached $152.26, a 52‑week high, after raising full‑year revenue guidance to $2.83‑$2.86 B and launching new prenatal testing services.
upward bias for the remainder of the year
Guidance lift and new service rollout signal growth momentum.
Twist Bioscience surged 16% to $185.22 after announcing a collaboration with Eli Lilly’s TuneLab for AI‑driven antibody discovery.
short‑term upside, potential long‑term upside if partnership yields products
Strategic partnership validates technology and opens new market opportunities.
Market effects
Biotech sector may see broader rally as multiple companies receive regulatory and commercial milestones.
U.S. biotech equities gain momentum, potentially lifting related ETFs.
Positive US biotech news can influence global health‑tech sentiment.
Counterpoint
Price spikes may be short‑lived if broader market sentiment turns risk‑off.
Key entities
- companyCareDx Inc.
Precision medicine firm for transplant patients.
- companyAdaptive Biotechnologies Corp.
Immunology‑focused biotech.
- companyRevvity Inc.
Health‑science solutions provider.
- companyTwist Bioscience Corp.
DNA‑based product manufacturer.
